With the decision of CEO Olivier Brandicourt to retire, Sanofi’s board chose Paul Hudson as his successor.
Christi L. Shaw will join Gilead Sciences Inc.’s subsidiary Kite as CEO and she will also become a member of Gilead’s senior leadership team.
Pluristem Therapeutics Inc. completed the transition period of the company’s co-CEO structure, appointing Yaky Yanay as sole CEO & president and Zami Aberman as executive chairman of the board.
Atara Biotherapeutics Inc. appointed Pascal Touchon as president, CEO, and member of the board of directors.
OncoCyte Corp. selected Ronald Andrews as CEO.
Harpreet Singh was named CEO of Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies.
Kymera Therapeutics Inc. appointed the company’s co-founder and chief scientific officer, Nello Mainolfi, Ph.D., as president.
Paratek Pharmaceuticals Inc. promoted Evan Loh, M.D., to CEO.
A2A Pharmaceuticals Inc. named Dr. Sotirios G. Stergiopoulos as president and CEO.
Raj Kannan was appointed CEO of Chiasma Inc.